Millions of Americans are expected to become eligible for GLP-1 medications for weight loss under a new Medicare demonstration program that begins July 1. The pilot will make certain branded GLP-1 products available to beneficiaries 65 and older or those with disabilities for a fixed monthly co-pay of $50, with coverage running through the end of 2027.
The demonstration explicitly includes multiple drug formulations: Novo Nordisk’s Wegovy is available in both injection and pill form; Eli Lilly’s Zepbound is included in its four-dose KwikPen injection configuration as well as Foundayo in pill form. The program does not cover single-dose Zepbound vials or single-use pens.
Eligibility criteria
Not every Medicare enrollee will qualify. Beneficiaries who already receive GLP-1 drugs under their existing Medicare prescription drug plans because of other medical conditions - such as type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease - are not the intended targets of this demonstration. For other Medicare participants to qualify, they must meet one of the following body mass index - BMI - thresholds:
- A BMI of 35 or above.
- A BMI of 30 or above combined with heart failure, uncontrolled hypertension or certain severe chronic kidney diseases.
- A BMI of 27 or above together with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
For context within the program: a BMI of 25-29.9 is classified as overweight, and a BMI greater than 30 is classified as obese.
Enrollment mechanics and clinical requirements
Coverage under the demonstration requires clinical steps before a pharmacy can dispense a covered GLP-1 drug. A prescribing clinician must send a prescription for an included GLP-1 product to the pharmacy and complete a prior authorization. The provider must also certify that the patient will use the drug as part of a lifestyle program emphasizing diet and exercise.
Clinical concerns for older adults
Clinicians caution that use of GLP-1 therapies in older adults requires careful clinical management. One primary concern is the loss of lean muscle mass that can accompany weight loss. In older patients, diminishing lean mass may exacerbate age-related muscle loss and frailty and could alter the absorption or effectiveness of other medications.
Obesity medicine specialists are therefore advising patients to combine resistance training with higher-protein diets to help preserve lean body mass during weight reduction. Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital, noted that clinicians typically recommend a protein intake in the range of 1.2 to 1.6 grams per kilogram of body weight per day to support muscle preservation during weight loss.
Rapid weight loss also poses risks for bone health. A decline in bone mineral density is a particular worry for postmenopausal women and older adults who already face increased risk of osteoporosis and fractures. To address this, clinicians are incorporating baseline DEXA scans to evaluate bone health, monitoring bone density over time, and ensuring adequate calcium and vitamin D intake for patients on these therapies.
Dr. John Batsis, a geriatric medicine specialist at the University of North Carolina at Chapel Hill, warned that access to the drug could expand more quickly than access to the necessary clinical support to use the medications safely and effectively.
Operational and fiscal unknowns
Several uncertainties remain about the pilot’s implementation and long-term prospects. It is not clear whether physicians and pharmacies will be fully prepared for the demand generated by the rollout. Equally uncertain is whether Medicare will extend or convert the demonstration into a permanent program after it concludes in December 2027.
There are substantial cost considerations tied to the demonstration. Medicare is paying roughly $250 per month for these therapies, of which the beneficiary pays $50. Depending on how many millions of eligible beneficiaries enroll, the total program cost could reach into the billions annually. Juliette Cubanski, a program director on Medicare policy at KFF, said the demonstration will be helpful for patients in the near term, but she cautioned that it "comes at a cost to the federal government and doesn’t really represent a sustainable approach to longer-term Medicare coverage of drugs used for weight loss."
What is clear and what is not
The demonstration expands access to specific GLP-1 medicines for many older Americans under defined BMI- and comorbidity-based criteria, requires prior authorization and certification of lifestyle support, and sets a standardized $50 monthly co-pay. What remains unresolved are provider readiness, the durability of coverage after 2027, and the fiscal sustainability of the approach if uptake is high.
As the program begins, clinicians and policy analysts will be watching both patient outcomes and the capacity of the healthcare system to deliver the necessary clinical oversight that preserves muscle and bone health while managing medication interactions and access logistics.